Study Details

Back
Study ID EGD-EC-003
Study Title A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in patients with relapsing or locally advanced prostate cancer who are responsive to such therapy
Clinicaltrials.gov Identifier NCT00378690
Compound Name ASP7015 / leuprorelin acetate
Medical Indication or Disease Prostate cancer
Study Sponsor Astellas Pharma Europe Ltd
Collaborator Not Applicable
Study Start Date 05-Apr-2006
Study Completion Date 08-Apr-2013
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS